TY - JOUR
T1 - Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients
AU - Shimomura, Yoshimitsu
AU - Hara, Masahiko
AU - Konuma, Takaaki
AU - Itonaga, Hidehiro
AU - Doki, Noriko
AU - Ozawa, Yukiyasu
AU - Eto, Tetsuya
AU - Uchida, Naoyuki
AU - Aoki, Jun
AU - Kato, Jun
AU - Onishi, Yasushi
AU - Takahashi, Satoshi
AU - Fukushima, Kentaro
AU - Nakamae, Hirohisa
AU - Kawakita, Toshiro
AU - Tanaka, Junji
AU - Fukuda, Takahiro
AU - Atsuta, Yoshiko
AU - Ishikawa, Takayuki
AU - Ishiyama, Ken
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021
Y1 - 2021
N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curable treatment option for adolescent and young adult (AYA) patients with myelodysplastic syndrome (MDS). The study aim was to evaluate epidemiological data and identify prognostic factors for AYA patients with MDS undergoing allogeneic HSCT. Here, 645 patients were selected from patients enrolled in a multicenter prospective registry for HSCT from 2000 to 2015. The primary endpoint was 3-year overall survival (OS). Survival rates were estimated using the Kaplan–Meier method. Prognostic factors were identified using the multivariable Cox proportional hazards model. The 3-year OS was 71.2% (95% confidence interval [CI]: 67.4–74.6%). In multivariable analysis, active disease status (adjusted hazard ratio: 1.54, 95% CI: 1.09–2.18, p = 0.016), poor cytogenetic risk (1.62, 1.12–2.36, p = 0.011), poor performance status (2.01, 1.13–3.56, p = 0.016), human leukocyte antigen (HLA)-matched unrelated donors (2.23, 1.39–3.59, p < 0.001), HLA-mismatched unrelated donors (2.16, 1.09–4.28, p = 0.027), and cord blood transplantation (2.44, 1.43–4.17, p = 0.001) were significantly associated with poor 3-year OS. In conclusion, in AYA patients with MDS the 3-year OS following allogeneic HSCT was 71.2%. Active disease status, poor cytogenetic risk, poor performance status, and donor sources other than related donors were associated with poor 3-year OS.
AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curable treatment option for adolescent and young adult (AYA) patients with myelodysplastic syndrome (MDS). The study aim was to evaluate epidemiological data and identify prognostic factors for AYA patients with MDS undergoing allogeneic HSCT. Here, 645 patients were selected from patients enrolled in a multicenter prospective registry for HSCT from 2000 to 2015. The primary endpoint was 3-year overall survival (OS). Survival rates were estimated using the Kaplan–Meier method. Prognostic factors were identified using the multivariable Cox proportional hazards model. The 3-year OS was 71.2% (95% confidence interval [CI]: 67.4–74.6%). In multivariable analysis, active disease status (adjusted hazard ratio: 1.54, 95% CI: 1.09–2.18, p = 0.016), poor cytogenetic risk (1.62, 1.12–2.36, p = 0.011), poor performance status (2.01, 1.13–3.56, p = 0.016), human leukocyte antigen (HLA)-matched unrelated donors (2.23, 1.39–3.59, p < 0.001), HLA-mismatched unrelated donors (2.16, 1.09–4.28, p = 0.027), and cord blood transplantation (2.44, 1.43–4.17, p = 0.001) were significantly associated with poor 3-year OS. In conclusion, in AYA patients with MDS the 3-year OS following allogeneic HSCT was 71.2%. Active disease status, poor cytogenetic risk, poor performance status, and donor sources other than related donors were associated with poor 3-year OS.
UR - http://www.scopus.com/inward/record.url?scp=85105816677&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105816677&partnerID=8YFLogxK
U2 - 10.1038/s41409-021-01324-8
DO - 10.1038/s41409-021-01324-8
M3 - Article
AN - SCOPUS:85105816677
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
ER -
